 | | Vol. 13.23 – 17 June, 2021 |
| |
|
|
| Researchers showed that microenvironmental cytokines, particularly CCL2, decorated cancer exosomes causing exosome accumulation in specific cell subsets and organs, with a greater abundance and variety found on breast cancer patient-derived exosomes.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists CRISPR-engineered RNA splice junctions to produce normal and early stage ductal carcinoma in situ breast epithelial cells that expressed only AIB1Δ4. These cells showed enhanced motility and invasion in 3D cell culture.
[Cancer Research] |
|
|
|
| The authors presented a next-generation sequencing methylation-based blood test called methylation DETEction of Circulating Tumor DNA designed for the optimal detection and monitoring of metastatic TNBC.
[npj Precision Oncology] |
|
|
|
| USP35 promoted the growth of ER+ breast cancer in vitro and in vivo, and reduced the sensitivity of ER+ breast cancer cells to endocrine therapies such as tamoxifen and fulvestrant.
[Cell Death & Disease] |
|
|
|
| Scientists exploited cytokine-induced killer cells’ expression of FcγRIIIa in combination with clinical-grade monoclonal antibodies to redirect their lytic activity in an antigen-specific manner, and reported the efficacy of this combined approach against TNBC.
[Oncoimmunology] |
|
|
|
| A library of 17 C1-single and C1/C20-double modified salinomycin analogs was screened to identify compounds with improved activity against breast cancer stem cells.
[Biomedicine & Pharmacotherapy] |
|
|
|
| Persistent cells were enriched for vimentinhigh sub-population, vimentin knockdown using siRNA approach decreased the invasive and sphere forming capacities as well as Akt phosphorylation in persistent cells, indicating that vimentin was involved in chemotherapeutic treatment-induced enhancement of TNBC aggressiveness.
[Cells] |
|
|
|
| Investigators constructed an integrin α2β1 targeting DGEA-modified liposomal doxorubicin platform for application in breast cancer therapy. Demonstrated in vitro and in vivo, the constructed platform exhibited improved antitumor ability.
[Molecular Pharmaceutics] |
|
|
|
| Using a previously established model of in vitro mineralization, the MDA-MB-231 human breast cancer cell line was induced using two osteogenic agents, inorganic phosphate and β-glycerophosphate, and direct monitoring of the mineralization process was conducted using Raman micro-spectroscopy.
[Laboratory Investigation] |
|
|
|
| Reverse transcription-quantitative polymerase chain reaction was performed to confirm the downregulation of circ_0044234 in triple negative tumors and cell lines versus non-triple negative ones.
[Cancer Cell International] |
|
|
|
| Through investigating cellular functions including cell proliferation and stem cell features, it was demonstrated that hypoxic cancer-associated fibroblasts exosomes transferred circHIF1A into breast cancer cells, which played an important role in cancer stem cell properties sponging miR-580-5p by regulating CD44 expression.
[Cell Death Discovery] |
|
|
|
| Researchers evaluated cell death in mammospheres from MCF-7 and primary tumor cells in response to curcumin loaded on graphene nanosheets. The nanocarriers graphene oxide and graphene quantum dots had no cytotoxic effect on Kerman male breast cancer/71 and MCF-7 tumor cells, while those loaded with curcumin induced death in more than 50% of tumor cells.
[Biomedical Materials] |
|
|
|
|
| The authors summarize key discoveries that aid the clinical translation of phosphoinositide 3-kinase alpha (PI3Kα) and PI3Kδ inhibitors, including the PI3Kα isoform-selective inhibitor alpelisib for the treatment of breast cancer, highlighting lessons learnt and future opportunities.
[Nature Reviews Drug Discovery] |
|
|
|
| Scientists explain the possible mechanism of the Hippo pathway in combating endocrine resistance, and conclude by recommending endocrine therapy in combination with therapies targeting the Hippo pathway in the study of endocrine-resistant breast cancers.
[Cancer Cell International] |
|
|
|
|
| Daiichi Sankyo Company, Limited and AstraZeneca announced that the first patient was dosed in DESTINY-Breast09, a Phase III trial evaluating the safety and efficacy of ENHERTU® with or without pertuzumab compared to standard of care as a potential first-line treatment in patients with HER2 positive metastatic breast cancer.
[Daiichi Sankyo Company, Ltd] |
|
|
|
|
| July 22 – 23, 2021
Virtual |
|
|
|
|
|
| | Institute of Oncology Research – Bellinzona, Switzerland |
|
|
|
| | University of Michigan – Ann Arbor, Michigan, United States |
|
|
|
| | Gilead Sciences, Inc. – Foster City, California, United States |
|
|
|
| | Icahn School of Medicine at Mount Sinai – New York City, New York, United States |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
